Temat: Precision Medicine - Prolib Integro

Skocz do pozycji: 1.

Tytuł:: Contrast-Enhanced Mammography (CEM) capability to distinguish molecular breast cancer subtypes
Autorzy:: Szpor, Joanna
Kargol, Jaromir
Piegza, Tomasz
Popiela, Tadeusz
Łuczyńska, Elżbieta
Rudnicki, Wojciech
Heinze, Sylwia
Opis:: With breast cancer ranking first among the most common malignant neoplasms in the world, new techniques of early detection are in even more demand than before. Our awareness of tumors’ biology is expanding and may be used to treat patients more efficiently. A link between radiology and pathology was searched for in our study, as well as the answer to the question of whether a tumor type can be seen on contrast-enhanced mammography and if such knowledge may serve as part of precision medicine.
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego

Artykuł

na półce

Skocz do pozycji: 2.

Tytuł:: Precision medicine and improving the outcomes of atrial tachycardia ablation: a comprehensive review
Autorzy:: Młyński, Mikołaj
Kozłowski, Dariusz
Sławiński, Grzegorz
Wydawca:: Medical University of Gdańsk
Cytata wydawnicza:: Młyński M, Sławiński G, Kozłowski D. Precision medicine and improving the outcomes of atrial tachycardia ablation: a comprehensive review. Eur J Transl Clin Med. 2024;7(1):5-15. DOI: 10.31373/ejtcm/190469
Opis:: Atrial tachycardia (AT) is a prevalent cardiac arrhythmia characterized by rapid, abnormal electrical activity originating from the atria. It represents a significant clinical challenge due to its potential for recurrence, adverse cardiovascular outcomes and impact on quality of life. Catheter ablation has emerged as a primary therapeutic modality for AT, offering the potential for rhythm control and symptom alleviation. Despite advancements in techniques and technology, the success of AT ablation can vary widely among patients. Identifying prognostic factors associated with successful AT ablation and potential outcome improving techniques is imperative for optimizing patient care.
Dostawca treści:: Repozytorium Centrum Otwartej Nauki

Artykuł

na półce

Skocz do pozycji: 3.

Tytuł:: Applications of artificial intelligence and machine learning in microbial diagnostics and identification
Autorzy:: Sharma, Mohit
Chaturvedi, Navaneet
Yadav, Manoj Kumar
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego

Artykuł

na półce

Skocz do pozycji: 4.

Tytuł:: Precision medicine and improving the outcomes of atrial tachycardia ablation: a comprehensive review
Autorzy:: Młyński, Mikołaj
Sławiński, Grzegorz
Kozłowski, Dariusz
Tematy:: atrial tachycardia
catheter ablation
prognostic factors
procedural technique
precision medicine; Pokaż więcej
Wydawca:: Gdański Uniwersytet Medyczny
Powiązania:: https://bibliotekanauki.pl/articles/33894933.pdf Link otwiera się w nowym oknie
Opis:: Atrial tachycardia (AT) is a prevalent cardiac arrhythmia characterized by rapid, abnormal electrical activity originating from the atria. It represents a significant clinical challenge due to its potential for recurrence, adverse cardiovascular outcomes, and impact on patients' quality of life. Catheter ablation has emerged as a primary therapeutic modality for AT, offering the potential for rhythm control and symptom alleviation. Despite advancements in ablation techniques and technology, the success of AT ablation can vary widely among patients. Identifying prognostic factors associated with successful ablation and potential outcome improving techniques is imperative for optimizing patient care.
Dostawca treści:: Biblioteka Nauki

Artykuł

na półce

Skocz do pozycji: 5.

Tytuł:: Personalizacja – przyszłość medycznych konopi?
Personalization: the future of medical cannabis?
Autorzy:: Kurowska, Patrycja
Giermaziak, Wojciech
Tematy:: medycyna spersonalizowana
medycyna precyzyjna
marihuana lecznicza
Personalized Medicine
Precision Medicine
medical marijuana; Pokaż więcej
Wydawca:: Polskie Towarzystwo Farmaceutyczne
Powiązania:: https://bibliotekanauki.pl/articles/762611.pdf Link otwiera się w nowym oknie
Opis:: We live in the era of personalisation. Personalised advertisements attack us all around, we are proposed customised trainings and dietary plans. It is no different in medicine. Personalized medicine offers a special approach to the specific needs and symptoms of each patient. How is the future of medical cannabis drawn in the light of this concept? After all, the use of so-called "medical marijuana", although controversial, is the actual part of modern medicine. Approach to the principle: "one size fits all" does not work with therapeutic cannabis therapy. Cannabis is a complex herbal medicine, so far over five hundred compounds present in them have been identified and isolated - not only cannabinoids, but also terpenes, flavonoids and many other compounds. They are able to affect each other, causing so-called “entourage effect” (enhancing, synergetic effect). These interactions are responsible for specific action of different cannabis varieties. Choosing the right product is a huge challenge. There are hundred of different strains of cannabis. The global cannabis industry is full of different types and forms of products. Finding the right one for a patient struggling with specific condition can be a challenge. Gratefully, innovations allow higher levels of personalization while addressing challenges faced by a medical cannabis patient. Platforms using extensive data sets and artificial intelligence are being developed worldwide, which allow the development of personalized therapies based on cannabinoids, including for patients with cancer. However, there is a risk of abuse in this field. Especially since in Poland there is no proper law regarding genetic testing and biobanking... The other thing is that Cannabis flos, like other herbal medicinal products, can cause drug-drug interactions. As the medical cannabis market continues to evolve, we should all strive to ensure that the drug is adapted to the safety and therapeutic profile of the largest number of patients in need.
Żyjemy w erze personalizacji. Zewsząd atakują nas personalizowane reklamy, proponuje się nam dostosowane do naszych wymagań plany treningowe i dietę. Nie inaczej jest w medycynie. Medycyna spersonalizowana oferuje zindywidualizowane podejście do specyficznych potrzeb i objawów każdego pacjenta. Jak w świetle tej koncepcji rysuje się przyszłość konopi medycznych? W końcu stosowanie „medycznej marihuany”, choć budzi wiele kontrowersji, jest częścią współczesnej medycyny. Podejście w myśl zasady: „jeden rozmiar dla wszystkich” nie sprawdza się w przypadku terapii konopiami leczniczymi. Konopie siewne (Cannabis sativa L.) stanowią złożony lek roślinny, do tej pory zidentyfikowano i wyizolowano ponad 500 obecnych w nich związków – nie tylko kannabinoidów, ale również m.in. terpenów i flawonoidów. Mogą one między sobą oddziaływać, wywołując tzw. „efekt entourage”. Interakcje te odpowiadają za specyficzne działanie różnych odmian konopi. Wybór odpowiedniego produktu stanowi ogromne wyzwanie. Na świecie opracowuje się platformy wykorzystujące obszerne zbiory danych i sztuczną inteligencję, które pozwalają na opracowanie spersonalizowanych terapii opartych na kannabinoidach m.in. dla pacjentów z chorobą nowotworową. Istnieje jednak ryzyko nadużyć w tym zakresie. Ponieważ rynek medycznych konopi nadal ewoluuje, wszyscy powinniśmy dążyć do tego, aby lek był dostosowany pod kątem bezpieczeństwa i profilu terapeutycznego dla jak największej rzeszy potrzebujących go pacjentów.
Dostawca treści:: Biblioteka Nauki

Artykuł

na półce

Skocz do pozycji: 6.

Tytuł:: Allergic rhinitis – effective treatment according to the latest recommendations
Autorzy:: Arcimowicz, Magdalena
Tematy:: allergic rhinitis
ARIA
azelastine
EUFOREA
intranasal corticosteroids
MP-AzeFlu
precision medicine
treatment; Pokaż więcej
Wydawca:: Index Copernicus International
Powiązania:: https://bibliotekanauki.pl/articles/58465610.pdf Link otwiera się w nowym oknie
Opis:: Allergic rhinitis (AR) is a common chronic respiratory disease, that affects millions of individuals, has significant impact on their quality of life, productivity, and other comorbid conditions, including asthma and conjunctivitis. Despite a substantial burden on individuals, society and health economies, AR remains under-diagnosed, under-estimated and under-treated. Main symptoms defining this IgE-dependent inflammation of nasal mucosa are: sneezing, itchy nose, rhinorrhoea and nasal congestion. Real-world data obtained by mobile technology offer new insights into AR phenotypes and therapy. Clinical management aims to relieve or control symptoms, resolve allergic inflammation, and potentially induce allergen tolerance, using allergen immunotherapy. Most cases of AR respond rather satisfied to pharmacotherapy. A very useful tool, especially recommended for everyday clinical practice, is VAS (visual analogue scale) which can help with: to assessing the intensity of AR symptoms as well as choosing the most optimal therapeutic option. Pharmacological treatment of the condition should be safe; effective and easy to administer as we treat patients with chronic condition, sometimes for a long time. Most frequently used treatment of AR include oral, intranasal or ocular antihistamines, intranasal corticosteroids or combined intranasal antihistamines and corticosteroids. Based on real-life clinical experience it can be concluded that a fixed combination of intranasal corticosteroid and intranasal antihistamines (mainly MP-AzeFlu) may be considered to be most beneficial, particularly in monotherapy and AR resistant to previous treatment. Some AR patients are not satisfied with provided treatment results when the disease becomes only partially controlled. We still have unmet patients needs and we are still looking for better therapeutic options in this area. New initiatives such as EUFOREA are developed in parallel with existing ones, such as ARIA to integrate patients and healthcare professionals in the therapeutic process and create new recommendations that are closest to the idea of precision medicine, delivering the right treatment to the right patient at the right time.
Dostawca treści:: Biblioteka Nauki

Artykuł

na półce

Skocz do pozycji: 7.

Tytuł:: Tackling Current Biomedical Challenges With Frontier Biofabrication and Organ-On-A-Chip Technologies
Autorzy:: Maiullari, Fabio
Rizzi, Roberto
Paradiso, Alessia
Barbetta, Andrea
Volpi, Marina
Święszkowski, Wojciech
Bearzi, Claudia
Zhang, Yu Shrike
Fornetti, Ersilia
Gargioli, Cesare
Presutti, Dario
Celikkin, Nehar
Costantini, Marco
Agarwal, Tarun
Wydawca:: Frontiers Media
Cytata wydawnicza:: Celikkin N, Presutti D, Maiullari F, Fornetti E, Agarwal T, Paradiso A, Volpi M, Święszkowski W, Bearzi C, Barbetta A, Zhang YS, Gargioli C, Rizzi R and Costantini M (2021) Tackling Current Biomedical Challenges With Frontier Biofabrication and Organ-On-A-Chip Technologies. Front. Bioeng. Biotechnol. 9:732130. doi: 10.3389/fbioe.2021.732130
Opis:: In the last decades, biomedical research has significantly boomed in the academia and industrial sectors, and it is expected to continue to grow at a rapid pace in the future. An in-depth analysis of such growth is not trivial, given the intrinsic multidisciplinary nature of biomedical research. Nevertheless, technological advances are among the main factors which have enabled such progress. In this review, we discuss the contribution of two state-of-the-art technologies–namely biofabrication and organ-on-a-chip–in a selection of biomedical research areas. We start by providing an overview of these technologies and their capacities in fabricating advanced in vitro tissue/organ models. We then analyze their impact on addressing a range of current biomedical challenges. Ultimately, we speculate about their future developments by integrating these technologies with other cutting-edge research fields such as artificial intelligence and big data analysis.
This study was supported by the National Science Centre—Poland (NCN) within the POLONEZ 3 fellowship number 2016/23/P/NZ1/03604 which has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 665778. This study is also supported by the National Science Centre Poland (NCN) within PRELUDIUM 19 Project No. 2020/37/N/ST5/03272 to NC. This work was also supported by the National Science Centre (NCN) under the Grant No.: UMO-2016/23/Z/ST8/04375 (BIOMEMBRANE project (M-ERA.NET2 project 4246)).
Dostawca treści:: Repozytorium Centrum Otwartej Nauki

Artykuł

na półce

Skocz do pozycji: 8.

Autorzy:: Sokołowska Dąbek, Dąbrówka
Silicki, Jurand
Patyk, Mateusz
Mazur, Rafał
Kręcichwost, Roksana
Zaleska-Dorobisz, Urszula
Opis:: Radiomics is a new concept that has been functioning in medicine for only a few years. This idea, created recently, relies on processing innumerable quantities of metadata acquired from every examination, followed by extraction thereof from relevant imaging examinations, such as computer tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) images, by means of appropriate created algorithms. The extracted results have great potential and broad possibilities of application. Thanks to these we can verify efficiency of treatment, predict locations of metastases of tumours, correlate results with histopathological examinations, or define the type of cancer more precisely. In effect, we obtain more personalised treatment for each patient, which is extremely important and highly recommendable in the tests and applicable treatment therapies conducted nowadays. Radiomics is a non-invasive and high efficiency post-processing method. This article is intended to explain the idea of radiomics, the mechanisms of data acquisition, existing possibilities, and the challenges incurred by radiologists and physicians at the stage of making diagnosis or conducting treatment.
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego

Artykuł

na półce

Skocz do pozycji: 9.

Tytuł:: Cutaneous toll-like receptor 9 pre-defines hydroxychloroquine dosage in patients with both discoid and subacute lupus erythematosus
Autorzy:: Englert, Karolina
Migacz-Gruszka, Kamila
Jarosz-Chudek, Aleksandra
Szpor, Joanna
Dyduch, Grzegorz
Jaworek, Andrzej
Wojas-Pelc, Anna
Mercuri, Santo Raffaele
Spałkowska, Magdalena
Mazzoccoli, Gianluigi
Kłosowicz, Agata
Damiani, Giovanni
Opis:: Background and Objectives: Cutaneous lupus erythematosus (CLE) presents clinically heterogeneous manifestations, partially explained by the different expression of Toll-like receptors (TLRs) type 8 and 9, located to endosomal compartments where they are poised to recognize microbial nucleic acids. This disease is empirically treated with hydroxychloroquine (HCQ), which is hallmarked with a safe and effective profile, but induces a slow and sometimes clinically insufficient therapeutic response. Currently, no biomarkers predictive of response are validated or even proposed in the scientific literature. We aimed to evaluate endosomal TLR type 7, 8 and 9 as predictive biomarkers of HCQ efficacy. Materials and Methods: We conducted a case–control study comparing CLE patients retrospectively assigned to three subgroups based on 3–6-month Cutaneous LE Disease Area and Severity Index (CLASI) reduction upon treatment with HCQ (I = <40% vs. II = 40–80% vs. III = >80%). Before HCQ, lesional skin specimens were collected in untreated CLE and through immunohistochemistry; TLR-7, -8 and -9 expression was evaluated in the epidermis and the lymphocytic infiltrate was evaluated in the dermis. Results: Sixty-six lesional skin biopsies were compared with healthy controls. CLE patients displayed lower epidermal expression of total TLR 8 and 9 as well as infiltrating TLR-8, TLR9 + lymphocytes compared to controls. High HCQ responders differed from low responders for TLR-9 positivity (high vs. low) and for the lymphocytic dermal infiltrate (high vs. low). Conclusions: TLR9 could be envisaged as a possible biomarker to predict HCQ response level and dosage in CLE patients.
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego

Artykuł

na półce

Informacja

Wyszukujesz frazę "Precision Medicine" wg kryterium: Temat